B+
Bull case
0%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
BCRX
BioCrystANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
The Q2 earnings transcript is constructive on revenue growth, cash generation, ORLADEYO demand, pediatric rollout, and pipeline execution. However, the September 8 news flow was mixed with a negative headline tied to a reported PHVS trial win. Exact post-release price reaction, analyst revisions, options skew, short interest, employee sentiment, and social coverage were not supplied; missing data is not positive evidence. [#PR-EARNINGS-2026-08-12]
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventORLADEYO pediatric oral-pellet rolloutHigh impact
Pediatric oral-pellet shipments began in early August; management reported 47 prescriptions through July 31 and strong initial authorization activity, while paid conversion and real-world outcomes remain unproven. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-12]
2026-12-31catalystBCX17725 Netherton syndrome dataHigh impact
Management said the proof-of-concept trial is enrolling well and expects data by year-end 2026. This is an early clinical program with meaningful development risk. [#PR-EARNINGS-2026-08-12]
2027-03-31catalystNavenibart development progressionHigh impact
Management reported completion of enrollment in the largest blinded HAE trial to date. Future readout timing and efficacy data remain key unresolved value drivers. [#PR-EARNINGS-2026-08-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology